N-乙酰半胱氨酸联合双环醇治疗抗结核药物所致的药物性肝损伤患者疗效研究*

doi:10.3969/j.issn.1672-5069.2021.06.020

摘要/Abstract

摘要： 目的观察应用N-乙酰半胱氨酸(NAC)联合双环醇治疗抗结核药物所致的药物性肝损伤(DILI)患者的疗效。方法 2018年1月～2020年1月我院诊治的因肺结核接受抗结核药物治疗导致的DILI患者76例,随机分为A组38例和B组38例,分别给予双环醇或双环醇联合NAC治疗,两组均连续治疗1个月或至肝功能正常。因本组患者被发现得早,肝功能损害较轻,未停止抗结核治疗。采用黄嘌呤氧化法和硫代巴比妥酸法检测血清超氧化物歧化酶(SOD)和丙二醛(MDA)水平,采用双抗体夹心ELISA法检测血清白细胞介素-6(IL-6)水平,采用免疫散射速率比浊法检测血清C-反应蛋白(CRP)水平。结果在治疗结束时,B组血清AST、ALT和GGT水平分别为(39.3±10.5)U/L、(35.9±32.5)U/L和(58.4±10.5)U/L,显著低于A组【分别为(75.4±14.6)U/L、(86.9±44.8)U/L和(95.8±14.5)U/L,P<0.05】;B组血清SOD水平为(83.5±8.0)U/L,显著高于A组【(74.5±7.3)U/L,P<0.05】,而血清MDA、IL-6和CRP水平分别为(5.0±0.8)μmol/L、(4.1±1.2)ng/L和(9.1±2.2)mg/L,显著低于A组【分别为(6.9±1.2)μmol/L、(6.8±2.4)ng/L和(14.5±3.7)mg/L,P<0.05】;在治疗过程中,B组与A组出现头晕、腹泻、皮疹、发热和恶性呕吐发生率无显著性差异(18.4%对15.8%,P>0.05)。结论应用NAC联合双环醇治疗抗结核药物所致的DILI患者可获得较好的治疗效果,能促进血清肝功能指标的恢复,可能与抑制了机体氧化应激和炎症反应有关,同时患者加用药物后也未明显增加用不良反应发生率,但其长期治疗效果还需要进一步观察。

关键词: 药物性肝损伤, 抗结核药物, N-乙酰半胱氨酸, 双环醇, 治疗

Abstract: Objective This study aimed to investigate the efficacy of N-acetylcysteine (NAC) and dicyclol combination in the treatment of patients with antituberculous drugs-induced liver injury (DILI). Methods Seventy-six patients with DILI caused by anti-tuberculocidal agents for pulmonary tuberculosis were enrolled in our hospital between January 2018 and January 2020, and were randomly divided into group A and group B, with 38 cases in each group. All patients received symptomatic supporting treatment and nutritional supplement without discontinuing antituberculosis medication. The patients in group A were treated with bicyclol, and those in group B received bicyclol and NAC combination therapy for one month or didn't stop until serum liver function tests recovered. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL), gamma glutamine transferase (GGT), superoxide dismutase (SOD), malondialdehyde (MDA), interleukin-6 (IL-6) and C-reactive protein (CRP) levels were detected. Results At the end of treatment, serum AST, ALT and GGT levels in group B were (39.3±10.5)U/L, (35.9±32.5)U/L and (58.4±10.5)U/L, significantly lower than [(75.4±14.6)U/L, (86.9±44.8)U/L and (95.8±14.5)U/L, respectively, P<0.05] in group A; serum SOD level was (83.5±8.0)U/L, significantly higher than [(74.5±7.3)U/L, P<0.05], while serum MDA, IL-6 and CRP levels were (5.0±0.8)μmol/L, (4.1±1.2)ng/L and (9.1±2.2)mg/L, all significantly lower than [(6.9±1.2)μmol/L, (6.8±2.4)ng/L and (14.5±3.7)mg/L, respectively, P<0.05] in group A; the complications such as dizziness, diarrhea, rash, fever, and nausea and vomiting in the two groups were not significantly different (18.4% vs. 15.8%, P>0.05). Conclusion The administration of bicyclol and NAC combination in treatment of patients with DILI caused by anti-tuberculosis agents could achieve a good curing efficacy with improved recovery of liver function index, which might be related to the inhibition of oxidative stress and inflammatory reactions. The long-term efficacy still needs further observation.

Key words: Drug-induced liver injury, Anti-tuberculous agents, N-acetylcysteine, Bicyclol, Therapy

杜云飞, 刘景瑞, 叶飞翔. N-乙酰半胱氨酸联合双环醇治疗抗结核药物所致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 847-850.

Du Yunfei, Liu Jingrui, Ye Feixiang. Efficacy of N-acetylcysteine and dicyclol combination in the treatment of patients with antituberculous drugs-induced liver injury[J]. Journal of Practical Hepatology, 2021, 24(6): 847-850.

参考文献

[1] Hall RG. Evolving Larger: Dosing anti-tuberculosis (TB) drugs in an obese world. Cur Pharm Des, 2015, 21(32):4748-4751.
[2] Yuliwulandari R, Susilowati R W, Wicaksono B D, et al. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet, 2016, 61(6):533-537.
[3] 马玙, 卜建玲, 陈效友. 重视抗结核药物性肝损伤. 中华结核和呼吸杂志, 2013, 36(10):723-725.
[4] Shi J, Xie M, Wang J, et al. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. Pharmacogenomics, 2015, 16(18):2083-2097.
[5] Gafar F, Arifin H, Jurnalis Y D, et al. Antituberculosis drug-induced liver injury in children: incidence and risk factors during the two-month intensive phase of therapy. Pediatr Infect Dis J, 2019, 38(1):50-53.
[6] Dai H J, Li D W, Wang Y X, et al. Induction of heat shock protein 27 by bicyclol attenuates d-galactosamine/lipopolysaccharide-induced liver injury. Eur J Pharmacol, 2016, 15(791):482-490.
[7] Li X, Zhou J, Chen S, et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res, 2014, 42(4):906-914.
[8] Owumi S E, Andrus J P, Herzenberg L A, et al. Co-administration of N-Acetylcysteine and acetaminophen efficiently blocks acetaminophen toxicity. Drug Dev Res, 2015, 76(5):251-258.
[9] Rao J, Zhang C, Wang P, et al. C/EBP homologous protein (CHOP) contributes to hepatocyte death via the promotion of ERO1α signalling in acute liver failure. Biochem J, 2015, 466(2):369-378.
[10] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南.中华肝脏病杂志,2015, 23(11):810-820.
[11] 中华医学会结核病学分会, 结核病病理学诊断专家共识编写组. 中国结核病病理学诊断专家共识. 中华结核和呼吸杂志, 2017, 40(6):419-425.
[12] 罗雁, 陈营清, 孙丽,等. 抗结核药致药物性肝损伤的临床分析. 中华传染病杂志, 2007, 25(4):247-249.
[13] Bolt H M . Highlight report: biomarkers of acetaminophen-induced liver injury. Arch Toxicol, 2015, 89(11):2193-2194.
[14] 刘立伟, 赵新颜. 药物性肝损伤临床与组织病理学特点. 实用肝脏病杂志, 2019, 22(2):160-163.
[15] Alshammari G M, Balakrishnan A, Chinnasamy T . 2-hydroxy-4-methoxy benzoic acid attenuates the carbon tetra chloride-induced hepatotoxicity and its lipid abnormalities in rats via anti-inflammatory and antioxidant mechanism. Inflammation, 2017, 66(12):753-763.
[16] Yu H Y, Wang B L, Zhao J, et al. Protective effect of bicyclol on tetracycline-induced fatty liver in mice. Toxicology, 2009, 261(3):112-118.
[17] Shang W, Feng Y, Li J, et al. Effect of bicyclol tablets on drug induced liver injuries after kidney transplantation. Open Medicine, 2017, 12(1):62-69.
[18] Chen X, Zhang J, Han C, et al. A sexual dimorphism influences bicyclol-induced hepatic heat shock factor 1 activation and hepatoprotection. Mol Pharmacol, 2015, 88(1):38-47.
[19] Ozgur E, Sahin D, Tomruk A, et al. The effects of N-acetylcysteine and epigallocatechin-3-gallate on liver tissue protein oxidation and antioxidant enzyme levels after the exposure to radiofrequency radiation. Int J Radiat Biol, 2015, 91(2):187-193.
[20] Jones A L, Jarvie D R, Simpson D, et al. Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. Aliment Pharmacol Ther, 2015, 11(4):787-791.

N-乙酰半胱氨酸联合双环醇治疗抗结核药物所致的药物性肝损伤患者疗效研究^*

Efficacy of N-acetylcysteine and dicyclol combination in the treatment of patients with antituberculous drugs-induced liver injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	汤磊, 邹桂舟. 外科疾病导致的胆源性肝损伤诊治现状[J]. 实用肝脏病杂志, 2021, 24(6): 769-771.
[2]	姜浩, 张雯, 陈霞. 长效干扰素联合利巴韦林治疗慢性丙型肝炎患者疗效及其对静息能量消耗和营养状态的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 815-818.
[3]	黄飞虎, 薛建亚, 朱咏梅, 余姣, 王丽艳, 鲁琼. 应用索磷布韦/维帕他韦治疗门诊和住院筛查的丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 819-822.
[4]	肖金玉, 王延峰, 文小霞. 自身免疫性肝炎患者血清趋化因子CCL4和CXCL10水平及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(6): 827-830.
[5]	华琪, 陈琦, 游览. 142例抗结核药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 843-846.
[6]	刘玉玲, 甄增国, 王慧娟, 万秀敏, 郭振凯. 益生菌制剂对肝硬化并发自发性细菌性腹膜炎患者肠道屏障功能的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 867-870.
[7]	黄力鸥, 吴春荣, 徐丹, 崔宇慧, 唐建国. 无肝素化连续性肾脏替代治疗肝硬化并发肝性脑病患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 875-878.
[8]	王菁, 毕宁, 方亮, 田园. 自体骨髓干细胞经肝动脉肝内移植治疗失代偿期乙型肝炎肝硬化患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 887-890.
[9]	束青华, 张楠楠, 葛勇胜. 不同HCV基因型感染的慢性丙型肝炎和肝硬化患者对重组人干扰素α-2a治疗应答的影响[J]. 实用肝脏病杂志, 2021, 24(6): 899-902.
[10]	俞士刚, 田佳, 吴铁, 樊书荣. 损伤控制性手术对创伤性肝破裂患者生存及相关应激指标的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 915-918.
[11]	蔡创, 范若英, 李伟, 吴胜, 田宇剑, 唐晓明, 金勇, 周城臣. 十二指肠乳头旁憩室对ERCP手术治疗胆总管结石患者效果的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 919-922.
[12]	梁晨, 郑素军. Wilson病治疗研究现状^*[J]. 实用肝脏病杂志, 2021, 24(6): 930-933.
[13]	李伟之, 李培杰, 马富权, 刘梦莹, 薛挥. 应用利伐沙班抗凝治疗经皮血管内介入治疗的布加综合征患者疗效和安全性研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 621-624.
[14]	李伟, 宋卫东, 谢巴图白音. 采用EVL或TIPS治疗肝硬化并发食管静脉曲张出血患者疗效及其预后分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 629-632.
[15]	季旻游, 李超, 赵兴忠, 武煦峰. 恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化患者疗效及对肠道菌群的影响^*[J]. 实用肝脏病杂志, 2021, 24(5): 641-644.